Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.52 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.52 |
| ▸ | PIKFYVE | Q9Y2I7 | 9/20 | 0.51 |
| ▸ | FES | P07332 | 1/20 | 0.51 |
| ▸ | FER | P16591 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | FRK | P42685 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120640 | 1.00 | KDM4E (0.59) | KDM4EMAPTLMNAHPGDEHMT2 | |
| SCHEMBL429159 | 0.84 | PIKFYVE (0.66) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL429158 | 0.84 | PIKFYVE (0.66) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL429384 | 0.84 | MAPT (0.59) | KDM4EMAPTLMNAHPGDEHMT2 | |
| SCHEMBL429383 | 0.84 | MAPT (0.59) | KDM4EMAPTLMNAHPGDEHMT2 | |
| SCHEMBL4134696 | 0.76 | MAPT (0.50) | KDM4EMAPTLMNAHPGDEHMT2 | |
| SCHEMBL4134693 | 0.76 | MAPT (0.50) | KDM4EMAPTLMNAHPGDEHMT2 | |
| SCHEMBL429036 | 0.75 | MAPT (0.77) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL429035 | 0.75 | MAPT (0.77) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL18330253 | 0.75 | MAPT (1.00) | KDM4EMAPTLMNAHPGDPIKFYVE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210140945-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES AND DISORDERS | MADRIGAL PHARMACEUTICALS INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20180217130-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | MADRIGAL PHARMACEUTICALS INC (US) | 2018-08-02 | — | — | US | disclosed |
| US-9910031-B2 | Compositions and methods for modulating c-Rel-dependent cytokine production | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160003804-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | ACADIA WOODS PARTNERS, LLC | 2016-01-07 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120208203-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-16 | — | — | US | disclosed |
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080227114-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007100759-A2 | METHOD FOR TREATING COMMON VARIABLE IMMUNODEFICIENCY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1682682-A4 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS CORP (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1682682-A2 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | Synta Pharmaceuticals Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050282232-A1 | Compositions and methods for modulating c-Rel-dependent cytokine production | SYNTA PHARMACEUTICALS CORP. | 2005-12-22 | — | — | US | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046619-A2 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | KDM4E 3523/4885MAPT 1771/4885LMNA 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.